Lung cancer and melanoma donors are the first research collaboration -
LUNGevity Foundation today announced a partnership with the Lung Cancer Alliance Foundation research and melanoma research to co-finance innovative new research on PD-1 options for the treatment of cancer inhibitor of both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases. The winner is Lucia Jilăveanu, MD, Ph.D., of Yale University, for his project Response to PD-1 inhibitors in melanoma and lung cancer patients with brain metastases.
Although responses to new systematic immune therapies have been encouraging, patients with brain metastases were generally excluded from clinical trials, leaving them with limited therapeutic options. Among those diagnosed with NSCLC and MM, about 50 000 patients each year develop brain metastases.
This first collaborative research between lung cancer and melanoma donors reflects the urgency divided on this issue. People with cancer non-small cell lung cancer (NSCLC) have the highest incidence of brain metastases among all cancers, and melanoma has the highest probability to metastasize to the brain once the disease is prevalent.
"LUNGevity Foundation is delighted to collaborate with Melanoma Research Alliance and the Research Foundation of lung cancer in the fight against a serious problem that affects both of our communities," said LUNGevity Foundation President Andrea Stern Ferris. "Immunotherapy is one of the most promising areas of medical science. To develop this progress for lung cancer patients with brain metastases could open a world of treatment of 50,000 people each year who have not yet been able to access this vital treatment. "
EmoticonEmoticon